Tenet Anticipates Beating Midpoint of Latest 2022 Outlook; Announces Key Leadership Updates
Tenet Healthcare Corporation (NYSE: THC) anticipates exceeding the midpoint of its FY22 Adjusted EBITDA Outlook, projected at $3.425 billion, despite not finalizing all financials. CEO Saum Sutaria highlighted strong management capabilities across all business units. Leadership updates include the retirement of key executives, with ongoing searches for successors. Daniel Cancelmi and Brett Brodnax will retire at the end of 2023, while Roger Davis will step down in Q1 2023. New promotions within operational leadership aim to enhance strategic execution and operational consistency, reinforcing Tenet's commitment to performance.
- Expecting FY22 Adjusted EBITDA to exceed $3.425 billion.
- Strong performance across all business units.
- Effective leadership transition planned with new promotions.
- Retirement of key executives may disrupt continuity.
- Leadership changes could introduce uncertainty during transition.
Although Tenet’s financial statement close process is not yet fully completed, the Company anticipates its Adjusted EBITDA, excluding any fourth quarter stimulus grant income related to the pandemic, will be slightly above the mid-point of its Adjusted EBITDA guidance of
“Our business units continued to demonstrate effective management capabilities and delivered strong results in the fourth quarter,” said
Additionally, Tenet announced leadership updates and operational organizational changes aligned with the company’s strategic priorities and designed to help ensure continued performance.
The announcement includes the retirement of
“Dan was instrumental in the recent transformation of Tenet’s performance and improvement of the balance sheet,” said Sutaria. “Dan is an inspirational leader with a long legacy at Tenet, starting as a hospital CFO to becoming our corporate CFO. He is a tireless advocate for our people and company. The strength of our finance function at Corporate and across our business units is a testament to Dan’s leadership, operational acumen, and commitment to Tenet.”
The retirement of
“Brett has not just positively shaped USPI, but the overall ambulatory surgery industry. He will always be a distinguished alumnus of the company and a supporter of USPI’s team, community of doctors, and health system partners,” said Sutaria. “Andy is well positioned to step into the USPI President role – he was previously USPI’s Chief Development Officer and Chief Operating Officer of the East Division. I will personally be spending more time with USPI to advance business goals and support the transition.”
Brett has also offered ongoing support in a non-management role after the end of 2023.
The announcement also included the retirement of
“Roger’s thoughtful leadership and commitment to client service has supported Conifer’s operational and commercial improvements,” said Sutaria. “I am confident in the team’s ability to continue Conifer’s positive trajectory.”
Furthermore,
In addition, the announcement also included the promotions of
“Tenet has exceptional talent throughout its operational ranks,” said Sutaria. “The Group Presidents have a track record for driving results, developing high performing teams, and enhancing access to care. I am confident in their ability to help lead our hospital segment.”
About
Non-GAAP Financial Measures
The Company has not provided the most directly comparable GAAP financial measure, or a quantitative reconciliation thereto, for its expected 2022 Adjusted EBITDA because at this time we have not yet finalized all the data to be able to reconcile certain forward-looking non-GAAP financial measures to the most comparable
Reconciliations of non-GAAP measures, such as Adjusted EBITDA, to the most comparable GAAP measures and management’s reasoning for using them are included in the Company’s earnings press release dated
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic and other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006041/en/
Investor Contact
469-893-2387
william.mcdowell@tenethealth.com
Media Contact
469-893-2640
mediarelations@tenethealth.com
Source:
FAQ
What is Tenet Healthcare's expected Adjusted EBITDA for FY22?
Who are the key executives retiring from Tenet Healthcare?
What are the leadership updates at Tenet Healthcare?